{"id":"efmoroctocog-alfa-injection-eloctate","safety":{"commonSideEffects":[{"rate":null,"effect":"Inhibitor development (anti-factor VIII antibodies)"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fever"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This fusion protein combines factor VIII (the missing or deficient clotting factor in hemophilia A) with human serum albumin, which extends the half-life of factor VIII in circulation. By providing functional factor VIII, the drug restores the intrinsic coagulation pathway and enables normal blood clot formation, reducing spontaneous and trauma-induced bleeding episodes.","oneSentence":"Efmoroctocog alfa is a recombinant human coagulation factor VIII fused to human serum albumin, which replaces deficient clotting factor VIII to restore hemostasis in hemophilia A patients.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:36:11.941Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hemophilia A (congenital factor VIII deficiency) — routine prophylaxis and on-demand treatment of bleeding episodes"}]},"trialDetails":[],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Efmoroctocog Alfa Injection [Eloctate]","genericName":"Efmoroctocog Alfa Injection [Eloctate]","companyName":"The League of Clinical Research, Russia","companyId":"the-league-of-clinical-research-russia","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Efmoroctocog alfa is a recombinant human coagulation factor VIII fused to human serum albumin, which replaces deficient clotting factor VIII to restore hemostasis in hemophilia A patients. Used for Hemophilia A (congenital factor VIII deficiency) — routine prophylaxis and on-demand treatment of bleeding episodes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":false,"score":3}}